Ratings WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 20/06/2025			5-day change	1st Jan Change
65.27 ^CNY	+0.52%		-3.60%	+18.59%

18/06	US-China Tensions Cause Delay in Chinese Drug Research Projects, Sources Say	MT
18/06	China pharma projects disrupted by Sino-US tensions	RE

Summary: WuXi AppTec Co., Ltd.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: WuXi AppTec Co., Ltd.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses: WuXi AppTec Co., Ltd.

With an enterprise value anticipated at 3.79 times the sales for the current fiscal year, the company turns out to be overvalued.

Ratings Chart: WuXi AppTec Co., Ltd.

Source: Surperformance

ESG chart: WuXi AppTec Co., Ltd.

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	WUXI APPTEC CO., LTD.				2.59TCr
	REGENERON PHARMACEUTICALS, INC.				5.43TCr
	ARGENX SE				3.31TCr
	GENMAB A/S				1.33TCr
	WUXI BIOLOGICS (CAYMAN) INC.				1.25TCr
	EXELIXIS, INC.				1.11TCr
	AKESO, INC.				1.05TCr
	Average				2.3TCr
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes